Detalles de la búsqueda
1.
Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma.
Future Oncol
; 12(23): 2683-2688, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27581765
2.
Outpatient management of pulmonary embolism in cancer: data on a prospective cohort of 138 consecutive patients.
J Natl Compr Canc Netw
; 12(3): 365-73, 2014 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24616542
3.
Gene-Expression Profiling to Decipher Breast Cancer Inter- and Intratumor Heterogeneity.
Cold Spring Harb Perspect Med
; 14(1)2024 Jan 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37137498
4.
Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.
NPJ Breast Cancer
; 10(1): 20, 2024 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38448600
5.
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
JAMA Oncol
; 10(5): 603-611, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38546612
6.
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 10(3): 362-371, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38236590
7.
Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer.
JAMA Netw Open
; 6(12): e2348814, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38117494
8.
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
JAMA Oncol
; 9(4): 490-499, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36602784
9.
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Nat Commun
; 14(1): 7053, 2023 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37923752
10.
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer.
J Clin Oncol
; 40(12): 1323-1334, 2022 04 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35044810
11.
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.
NPJ Breast Cancer
; 7(1): 1, 2021 Jan 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33397968
12.
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy.
Clin Cancer Res
; 27(11): 3116-3125, 2021 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33632929
13.
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
J Clin Oncol
; 38(35): 4184-4193, 2020 12 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33095682
14.
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.
Cancer Treat Rev
; 84: 101965, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-32000054
15.
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Front Oncol
; 9: 1178, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31750258
16.
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Front Oncol
; 9: 303, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31106144
17.
Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer.
Cancer Treat Rev
; 67: 63-70, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29763779
18.
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.
NPJ Breast Cancer
; 9(1): 32, 2023 Apr 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37120452
19.
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.
Oncotarget
; 8(13): 21930-21937, 2017 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28423537
20.
Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.
Immunotherapy
; 8(6): 687-92, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27115320